Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Sep 2014

Volume: 15

Issue: 10

Affiliations

[1 ] Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jaburger@mdanderson.org.

[2 ] Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.

[3 ] Institute of Pathology, University of Würzburg, Würzburg, Germany.

[4 ] Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.

[5 ] Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.

[6 ] Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, USA.

Article

Publisher Item ID: S1470-2045(14)70335-3 Mid ID: NIHMS626159

DOI: 10.1016/S1470-2045(14)70335-3

PubMed ID: 25150798

SO-VID: b0533dcf-1265-4981-a918-3b1ffea20e63

History

Data availability:

Comments

Comment on this article

scite_

Cited by 104

See all cited by

- Version 1